A pharmacy benefit manager stopped covering a GLP-1 for obesity. Now there’s a lawsuit

A class action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lily’s blockbuster GLP-1 drug to treat obesity.

​ A class action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lily’s blockbuster GLP-1 drug to treat obesity. Read More Breaking News, Latest News and Videos | CNN